Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma

Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma

Background/Objectives: Systemic chemotherapy is recommended for all stages of pancreatic ductal adenocarcinoma (PDAC), with a recent shift towards neoadjuvant chemotherapy (NAC) for resectable PDAC. The objective of this study was to compare outcomes of NAC versus AC for early stage resectable PDAC...

Full description

Bibliographic Details
Main Authors: Wade Christopher, Sean Nassoiy, Rebecca Marcus, Jennifer Keller, Shu-Ching Chang, Trevan Fischer, Anton Bilchik, Melanie Goldfarb
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Surgery in Practice and Science
Subjects:
Pancreas
Pancreatic adenocarcinoma
Resectable
Neoadjuvant
Online Access:http://www.sciencedirect.com/science/article/pii/S2666262022000778

Internet

http://www.sciencedirect.com/science/article/pii/S2666262022000778

Similar Items